Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

By sjmartinez • November 15, 2024

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e153. doi: 10.1017/cts.2024.607. PMID: 39540115; PMCID: PMC11557272.

Tags: Infectious Diseases, Publications

Related Posts

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Shafer RW, Tien PC, Baden LR, Cawcutt K, Chiotos K, Dzierba[...]

Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry

Agrawal P, Kumar P, Ali B, Nabeela S, Ikeh MAC, Morschhäuser J, Andes DR, Nobile CJ, Prasad R, Uppuluri P, Panwar SL. Lem3, a phospholipid[...]